Veraya BioStrategy. Initiate Dialogue —

Executive Dossier

Knowledge Library.

Strategic analogs detailing how we isolate commercial bottlenecks, apply precise analytical methodologies, and mandate executive action across the life sciences ecosystem.

Macro Cellular Biology

Data Enrichment & ML

Unmasking Undiagnosed Rare Disease Cohorts

Applying Positive-Unlabeled (PU) machine learning to fragmented claims datasets to identify high-probability patient cohorts where true negative labels do not exist.

Abstract Data Waves

Predictive Analytics

Temporal Trajectory Modeling for Pre-Symptomatic Intervention

Utilizing sequence-based machine learning on longitudinal Rx/Dx claims to predict disease progression months before standard clinical diagnosis.

Abstract Network Nodes

Network Analytics

Mapping Multi-Tier Influence Ecosystems in Oncology

Applying graph analytics to locate hidden community prescriber influence networks driving biologic uptake.

Geometric Glass Structure

Launch Analytics

Bayesian Trajectory Forecasting & Month 3 Course Correction

Integrating sub-national formulary approvals and HCP trial-decay logic to predict launch stall curves, enabling decisive resource reallocation.

Abstract Data Matrix

Commercial Analytics

Causal Machine Learning for Omnichannel Optimization

Moving beyond naive deciling by estimating heterogeneous treatment effects to direct field visits exclusively to persuadable HCP targets.

Sterile Lab Equipment

Real-World Data

Tracing Patient Attrition in Specialty Biomarker Testing

Constructing a deterministic journey waterfall to pinpoint the exact days where diagnosed patients abandon treatment due to administrative friction.

Biotech Abstract Structure

Portfolio Strategy

Dynamic Asset Valuation in Autoimmune Pipeline

Deploying stochastic market simulation to evaluate Phase II assets against future standard-of-care shifts, averting a significant sunk-cost commitment.

Market Access

Deconstructing Gross-to-Net Leakage in Competitive Immunology

Implementing contract-level profit mapping to renegotiate major PBM tiers, improving net margins significantly in a high-rebate environment.

Macro Network Texture

Fluid Abstract Dynamics

Growth Strategy

Accelerating Peak Year Sales in Cell & Gene Therapy

Utilizing process mining on site certification logs to cut clinical onboarding times, allowing the manufacturer to reach peak capacity early.

Data Enrichment & ML|Client: Mid-Cap Rare Disease Innovator

Unmasking Undiagnosed Rare Disease Cohorts

Cellular Biology

The Commercial Context

In rare disease markets, official ICD-10 diagnostic coding is chronically delayed or entirely absent in real-world data. Commercial teams struggle to deploy field forces efficiently because they cannot definitively identify where undiagnosed patients reside within regional health systems.

The Analytical Complication

Traditional supervised machine learning requires both confirmed 'positive' and confirmed 'negative' patients to train a predictive model. However, in claims data, an un-coded patient is not definitively 'negative'—they are merely 'unlabeled'. Forcing traditional binary classifiers onto this environment leads to severe model bias.

The Strategic Approach

We deployed an Elkan-Noto based Positive-Unlabeled (PU) Learning framework across a longitudinal claims dataset encompassing over 50 million covered lives. We isolated highly confident 'true negatives' and trained a Gradient Boosting ensemble to assign a latent probability score to the remaining 'unlabeled' mass based on longitudinal symptom phenotypes.

Executive Impact

The PU framework successfully identified 4,200 "look-alike" high-risk patients lacking the formal ICD-10 code but displaying identical symptom trajectories to confirmed patients. Commercial leadership instantly routed these unmasked HCP targets to specialized field teams, yielding a measured 31% uplift in diagnostic testing requisitions within 90 days.

Predictive Analytics|Client: Global Neurological Franchise

Temporal Trajectory Modeling for Pre-Symptomatic Intervention

Abstract Data Waves

The Commercial Context

For progressive neurological therapies, early intervention is critical to preserving irreversible functional loss. The optimal time to engage a physician with disease awareness is months before the patient exhibits late-stage symptoms.

The Analytical Complication

Physicians frequently fail to officially diagnose the condition until severe symptoms emerge. Commercial marketing efforts tied solely to formal diagnostic claim codes were activating far too late in the patient timeline, resulting in suboptimal clinical outcomes and lost market share to established generic stop-gaps.

The Strategic Approach

We bypassed cross-sectional static models and engineered a Recurrent Neural Network (RNN) architecture designed specifically for sparse, irregular time-series healthcare data. By embedding thousands of distinct medical interventions, lab orders, and minor procedural codes, the model learned the complex temporal sequence signatures that consistently precede clinical onset by 8 to 12 months.

Executive Impact

Marketing strategy successfully pivoted from 'post-diagnosis' engagement to 'pre-disease' unbranded awareness. By deploying highly targeted peer-to-peer (P2P) education to HCPs actively managing flagged high-probability cohorts, the brand accelerated diagnosis timeframes by an average of 4.2 months across the target population.

Network Analytics|Client: Top 10 Oncology Innovator

Mapping Multi-Tier Influence Ecosystems in Oncology

Network Nodes

The Commercial Context

A specialized oncology field team was deploying vast, expensive resources against high-decile Key Opinion Leaders (KOLs) at major academic medical hubs based on historical influence metrics.

The Analytical Complication

Localized script tracking revealed a structural gap: these academic KOLs rarely wrote the initial prescription. They were acting as surgical or second-opinion validators. Following validation, the actual treatment initiation and ongoing script volume fell back into a highly diffuse, untracked web of regional community hematologists.

The Strategic Approach

We ingested millions of deterministic claims pathways to construct a weighted directed graph of patient movement. Applying a modified PageRank algorithm and Louvain community detection, we bypassed basic decile math to isolate the 'true influence sinks'—highly connected community oncologists who routinely received validated patients from KOLs and initiated the long-term infusion regimens.

Executive Impact

The commercial blueprint was rewritten. Tier-1 access resources were shifted away from academic validators (retaining only medical affairs liaison support) and directly embedded into the 15% of community nodes that controlled 80% of actual treatment initiation weight, drastically reducing script abandonment post-KOL consult.

Launch Analytics|Client: Global Top 5 Pharma

Bayesian Trajectory Forecasting & Month 3 Course Correction

Geometric Strategy

The Commercial Context

At Week 12 of a high-profile immunology launch, top-line NBRx (New-to-Brand Prescriptions) appeared to perfectly match expected street targets. Executive dashboards indicated a successful, on-track launch phase.

The Analytical Complication

Standard volume reporting masked a critical underlying dynamic: heavy initial 'trialing' by early adopters was hiding a near-total failure of 'repeat' prescribing. Without repeat scripts, the mathematical reality guaranteed a severe trajectory cliff early in Quarter 2, putting the asset's entire fiscal year at risk.

The Strategic Approach

We replaced static linear forecasts with a Bayesian hierarchical model combining early leading indicators: P&T committee meeting velocity, localized access hurdles (Prior Auth rejection logs), and HCP trial-to-repeat conversion rates. The simulation deterministically proved the launch curve would stall at 40% below estimates due to regional administrative access friction dampening repeat clinical adoption.

Executive Impact

Armed with quantitative proof, leadership executed a "Code Red" field redirection. Dedicated market access personnel were stripped from low-friction zones and flooded into localized P&T friction hotspots, smoothing authorization pathways. The intervention averted the forecasted cliff, securing a $120M annual recurring run-rate trajectory.

Commercial Analytics|Client: Mid-Cap Specialty Pharma

Causal Machine Learning for Omnichannel Optimization

Data Matrix

The Commercial Context

Traditional commercial deployment universally relies on simple volume deciling: identifying the highest volume prescribers in a territory and maximizing physical sales rep frequency against them.

The Analytical Complication

Volume does not equal persuadability. This legacy model results in massive wasted spend by calling on "Sure Things" (brand loyalists who prescribe regardless of rep interaction) and "Lost Causes" (competitor loyalists who will never switch). The objective must shift from volume prediction to response elasticity prediction.

The Strategic Approach

We applied a Double Machine Learning causal inference framework to historic CRM interaction logs joined with longitudinal Rx outputs. By estimating the Heterogeneous Treatment Effect (HTE) of a physical field visit versus an email interaction, the model assigned an "Uplift Score" to every physician. Non-linear integer programming then mapped the constrained field force strictly to the highly elastic "Persuadable" quadrant.

Executive Impact

The revised commercial blueprint isolated 22% of historical Tier-1 targets as "Sure Things" and shifted them entirely to automated digital channels with zero negative impact on volume. The unlocked field capacity was hyper-concentrated onto mid-decile "Persuadables," generating a measured 18% net-new Rx volume lift with no additional commercial headcount.

Real-World Data|Client: Precision Oncology Biotech

Tracing Patient Attrition in Specialty Biomarker Testing

Lab Equipment

The Commercial Context

A specialty brand targeting a rare mutation observed acceptable diagnostic testing volumes, but lower-than-expected commercial fulfillment rates. The conversion pipeline from a positive NGS reflex test to an active, reimbursed commercial patient was failing.

The Analytical Complication

Standard syndicated data provided no granularity into the complex 6-week onboarding window. Leadership could see patients entering the funnel (Dx) and the few exiting it (Rx), but had zero visibility into exactly where, when, and why the majority were abandoning therapy in the middle.

The Strategic Approach

We engineered a deterministic patient journey waterfall utilizing rigorous survival analysis techniques. By linking probabilistic ICD-10 diagnostic coding, lab NGS reflex testing logs, and downstream 867 specialty pharmacy feeds, we calculated exact Kaplan-Meier abandonment probabilities at every micro-step of the access journey.

Executive Impact

The data proved failure was administrative, not clinical. The critical attrition vector occurred almost entirely between Prior Authorization (PA) Appeal 1 and Appeal 2. Leadership executed an immediate deployment of targeted Field Reimbursement Managers to these specific clinic clusters, reducing administrative time-to-therapy by 14 days and salvaging $22M in annual at-risk patient initiations.

Portfolio Strategy|Client: Global Immunology Leader

Dynamic Asset Valuation in Autoimmune Pipeline

Biotech Abstract

The Commercial Context

The client was evaluating a major Phase III clinical trial investment for an autoimmune asset that showed moderate efficacy improvements over current generics, but faced a rapidly changing future standard-of-care (SOC) landscape.

The Analytical Complication

Traditional Net Present Value (NPV) modeling relied on static Excel assumptions that assumed the current competitive landscape would remain frozen for the next 5 years. Leadership needed to understand the true risk profile if competitors launched expected biologicals before their own asset hit the market.

The Strategic Approach

We deployed a stochastic market simulation model running 10,000 Monte Carlo iterations. The model incorporated probabilistic competitor launch dates, varying levels of payer restriction, and physician adoption curves based on historical analog data. This allowed us to view the asset's valuation as a distribution of outcomes rather than a single static number.

Executive Impact

The simulation revealed a 65% probability that the asset would return a negative NPV if competitor biologics launched on time and secured Tier-2 formulary placement. Based on this rigorous quantitative risk assessment, the executive board decisively halted Phase III progression, averting a $400M sunk-cost commitment and reallocating funds to earlier-stage, highly differentiated assets.

Market Access|Client: Specialty Immunology Manufacturer

Deconstructing Gross-to-Net Leakage

Network Macro

The Commercial Context

A flagship immunology product was achieving strong top-line prescription growth, but profitability was eroding rapidly. High rebate demands from Pharmacy Benefit Managers (PBMs) were causing severe Gross-to-Net (GTN) leakage.

The Analytical Complication

Finance and Market Access teams were negotiating contracts in silos. Rebate walls were modeled at an aggregate national level, obscuring the fact that at certain local plan levels, the manufacturer was actually losing money on every marginal prescription filled due to stacked channel discounts and copay card utilization.

The Strategic Approach

We implemented a deterministic contract-level profit mapping system. By linking adjudicated claims data to specific PBM formulary contracts and patient copay program ledgers, we calculated the true net margin of every single prescription. We identified specific "toxic" contracts where the rebate demands exceeded the marginal value of the volume provided.

Executive Impact

The analysis empowered the Market Access team to aggressively renegotiate or walk away from deeply unprofitable regional PBM tiers. By optimizing the contract portfolio for net margin rather than raw volume, the manufacturer improved overall net margins by 12% in a highly competitive, high-rebate environment without sacrificing strategic market share.

Growth Strategy|Client: Rare Disease Gene Therapy Innovator

Accelerating Peak Year Sales in Cell & Gene Therapy

Fluid Abstraction

The Commercial Context

A novel Cell & Gene Therapy (CGT) launch was falling behind its peak year sales trajectory. Demand from key academic medical centers was high, but the complex institutional certification process required to administer the therapy was acting as a massive operational bottleneck.

The Analytical Complication

The institutional onboarding process involved legal contracting, specialized pharmacy handling, clinical training, and REMS compliance. The commercial team lacked visibility into where specific hospitals were stalling within this 6-to-9 month onboarding funnel, relying entirely on anecdotal feedback from Key Account Managers.

The Strategic Approach

We utilized process mining algorithms on the manufacturer's site certification and CRM logs to map the actual, un-idealized onboarding pathways of every hospital. We identified that the primary stalling point was not clinical training, but rather highly specific legal indemnification clauses stalling in hospital legal departments for an average of 45 days.

Executive Impact

Commercial operations immediately revamped the contracting workflow, deploying specialized legal concierges to preemptively address these clauses with hospital administration. The intervention cut average clinical onboarding times by 50%, unblocking 24 key academic centers and allowing the manufacturer to reach peak capacity and revenue targets two quarters early.